Unit of Internal Medicine, Department of Clinical and Experimental Medicine, 2nd University of Naples, Italy. Diabetes and Endocrinology Unit, St. Peter's Hospital FBF, Rome, Italy. Electronic address: felix.strollo@gmail.com. Unit of Gastroenterology, Department of Clinical and Experimental Medicine, 2nd University of Naples, Italy. Diabetes and Metabolic Disease Unit, Cardiovascular Department, IRCCS Multimedica, Sesto San Giovanni (MI), Italy. Instititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, (AC), Spain.
CONCLUSIONS Lispro granted lower early postprandial glucose levels and late postprandial hypoglycemic rates and therefore might represent the treatment of choice for people with T2DM and compensated CLD. This might depend on its faster/shorter-living effects, as well as, on the lower liver glucose output expected from its earlier hepatic distribution.